49th Annual Aspen Retinal Detachment Society Meeting

Add to Calendar 49th Annual Aspen Retinal Detachment Society Meeting 3/6/2021 4:00:00 PM 3/10/2021 7:30:00 PM America/New_York For More Details: https://beaumont.cloud-cme.com/course/courseoverview?EID=51304 Description: Founded in 1972, the ARDS holds an annual meeting the first week of March that attracts an outstanding group of retinal specialty leaders from around the world. The ARDS meeting is vigorous and defined by its interactive approach between the speakers and the audience. Dynamic discussion among all participants is a hallmark of the ARDS. false MM/DD/YYYY


Date & Location
Saturday, March 6, 2021, 4:00 PM - Wednesday, March 10, 2021, 7:30 PM EST

Overview
Founded in 1972, the ARDS holds an annual meeting the first week of March that attracts an outstanding group of retinal specialty leaders from around the world. The ARDS meeting is vigorous and defined by its interactive approach between the speakers and the audience. Dynamic discussion among all participants is a hallmark of the ARDS.

Target Audience
Specialties - Ophthalmology
Professions - Physician

Objectives
  1. Consider transitioning to small gauge vitrectomy surgery.
  2. Discuss tips and tricks for treating retinal detachment in highly myopic eyes.
  3. Describe combined surgical approaches to posterior and anterior pathology.
  4. Discuss macular reconstruction.
  5. Assess various pharmacologic therapies for non-AMD retinal diseases.
  6. Explain anti-VEGF therapy of neovascular AMD with advanced visual loss.
  7. Explain associations between reticular pseudodrusen and coronary artery disease.
  8. Consider utility of ultra-widefield swept source OCT.
  9. Identify microstructural macular changes after primary retinal detachment repair.
  10. Discuss transretinal tumor biopsies and their increasing importance for vitreoretinal surgeons.
  11. Discuss the different uses of anti-VEGF agents in multiple retinal diseases, including risks and benefits.
  12. Discuss the future uses of sustained delivery devices and gene therapy for long term delivery of anti-VEGF agents for retinal diseases.
  13. Summarize use of gene therapy for treatment of macular degeneration and diabetic retinopathy.
  14. Decrease endophthalmitis risk after intravitreal injections.
  15. Use advanced strategies for evaluating and treating radiation retinopathy.
  16. Evaluate new approaches in the management of posterior segment infections and inflammations .
  17. Discuss clinical implications and ethical responsibilities of laser and anti-VEGF treatment for ROP.
  18. Discuss the impact and implementation of the new ROP international classification.

Credits
AMA PRA Category 1 Credits™ (12.00 hours), AMA PRA Non-Physician (Attendance) (12.00 hours), Ethics (3.75 hours), Pain and Symptom Management (1.00 hours), Stroke CME (1.25 hours), Trauma CME (2.25 hours)

Credit Information

In support of improving patient care, this activity has been planned and implemented by Beaumont Health, Medical Conference Planners, Intl. and Aspen Retinal Detachment Society.  Beaumont Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine CME: Beaumont Health designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Specialty Credit
This conference is eligible for Pain and Symptom Management credit, Medical Ethics credit, Stroke CME credit, and Trauma CME credit.